#	Pagina
attuale pagina	/open-h2020/projects/198025/index.html
-1	/open-fp7/projects/109776/index.html
-2	/open-fp7/projects/88675/index.html
-3	/open-fp7/projects/107481/index.html
-4	/open-fp7/projects/108881/index.html
-5	/open-h2020/projects/205934/index.html
-6	/open-h2020/projects/205839/index.html
-7	/open-h2020/projects/208566/index.html
-8	/open-fp7/projects/107383/index.html
-9	/open-h2020/projects/193212/index.html
-10	/open-h2020/projects/226552/index.html

Opendata, web and dolomites

CHARME

Growing bone fast and cost-effective

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CHARME project word cloud

Explore the words cloud of the CHARME project. It provides you a very rough idea of what is the project "CHARME" about.

launch generation regeneration replace bv endpoints manufacture plan epitaxos defect biotechnology adverse spinal cell position technological body cells limited surface unlike inducing seduces marketing life graft put material strategy dental property attracting quantity stem trl6 establishment superiority billion trl standard successful form approval nano bone induces commercial patients autograft data 2017 quality acceptance exceptional procedure stimulate site operative epitaxo abundant pain million processed synthetic true quantities commercialisation faster superior xpand innovative channel autologous tissue patented structure technologies situ orthopaedic 200 generates charme patient regulatory allograft golden market markets maturity disadvantages submission extra clinically infrastructure materials

Project "CHARME" data sheet

The following table provides information about the project.

Coordinator	KUROS BIOSCIENCES BV Organization address address: PROFESSOR BRONKHORSTLAAN 10 G 48 city: BILTHOVEN postcode: 3723 MB website: www.xpand-biotech.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.charme-horizon.nl
Total cost	2˙630˙845 €
EC max contribution	1˙841˙591 € (70%)
Programme	1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-SMEINST-2-2014
Funding Scheme	SME-2
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2017-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KUROS BIOSCIENCES BV KUROS BIOSCIENCES BV Organization address address: PROFESSOR BRONKHORSTLAAN 10 G 48 city: BILTHOVEN postcode: 3723 MB website: www.xpand-biotech.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (BILTHOVEN)	coordinator	1˙841˙591.00

Map

Project objective

XPAND Biotechnology BV has developed a new generation of orthopaedic materials: the EpitaxOs bone regeneration material.

EpitaxOs (TRL 6) is unique: a) it seduces the body to form bone b) is as effective as the golden standard autograft without its disadvantages (extra operative procedure, pain, limited quantity available) c) it is superior to other synthetic bone graft materials, allograft, growth factors and cell-based technologies d) it is available in abundant quantities e) it increases the quality of life for patients as the use of EpitaxOs has no adverse effects on the patient. The innovative property of EpitaxOs is its patented surface nano-structure, which induces the formation of bone by attracting the patient’s own stem cells to the defect site and stimulate them to make autologous bone (in situ bone tissue regeneration). Similar to autograft and growth factors and unlike other synthetic materials, EpitaxOs is a true bone inducing material, but generates bone much faster

EpitaxOs is targeted at the €4 billion spinal market and the €200 million dental market. The exceptional bone inducing properties of EpitaxOs put it in a unique position to replace autograft, (processed) allograft and growth factors.

The CHARME project aims at bringing EpitaxOs from technological maturity level TRL6 to a successful commercial/ production launch at level TRL 8/9 (in 2017). The objectives are: 1. Development of a commercial scale production infrastructure 2. Regulatory submission of EpitaxOs in key markets 3. Providing evidence-based data to demonstrate product superiority and facilitate product launch & market acceptance 4. Establishment of a marketing channel and development of a strategy for commercialisation of EpitaxOs

The endpoints of the CHARME project will be EpitaxO, a commercial scale infrastructure, to manufacture EpitaxOs, regulatory submission, approval in Europe, clinically relevant study data, a marketing channel, plan for the commercialisation

Deliverables

List of deliverables.
Distribution targeted information letters to dedicated groups	Other	2019-07-25 13:42:30
Scientific articles	Documents, reports	2019-07-25 13:42:30
Brochures for patients, surgeons, hospitals	Other	2019-07-25 13:42:30
Establish an interactive CHARME webpage.	Other	2019-07-25 13:42:30

Take a look to the deliverables list in detail: detailed list of CHARME deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHARME" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHARME" are provided by the European Opendata Portal: CORDIS opendata.